Sex differences and the role of estrogen in animal models of schizophrenia: Interaction with BDNF

Neuroscience

Volumn 239, Issue , 2013, Pages 67-83

  Wu, Y C ^a,b   Hill, R A ^a,b   Gogos, A ^a,b   Van Den Buuse, M ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Dopamine; NMDA receptor; Psychiatric disorders; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CLOZAPINE; DOPAMINE; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; FLUOXETINE; GLUTAMINE; HALOPERIDOL; MESSENGER RNA; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN; VENLAFAXINE;

BDNF GENE; BIOACCUMULATION; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; DEPRESSION; DOPAMINERGIC ACTIVITY; DRUG RECEPTOR BINDING; DRUG TARGETING; ESTROGEN ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; ESTROGEN SYNTHESIS; GENE; GENE MUTATION; GENETIC MANIPULATION; HORMONAL REGULATION; HUMAN; MENSTRUAL CYCLE; MOLECULAR INTERACTION; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROPSYCHIATRY; NEUROTOXICITY; NONHUMAN; POSITIVE SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INTERACTION; PUERPERAL PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SEX DIFFERENCE;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 84876085536     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.10.024     Document Type: Review

References (234)

1. Aguirre C.C., Baudry M. Progesterone reverses 17beta-estradiol-mediated neuroprotection and BDNF induction in cultured hippocampal slices. Eur J Neurosci 2009, 29:447-454.
2. Ahokas A., Aito M., Rimon R. Positive treatment effect of estradiol in postpartum psychosis: a pilot study. J Clin Psychiatry 2000, 61:166-169.
3. Aleman A., Kahn R.S., Selten J.P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 2003, 60:565-571.
4. Angelucci F., Brene S., Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005, 10:345-352.
5. Angelucci F., Mathe A.A., Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000, 60:783-794.
6. Arad M., Weiner I. Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone. Psychopharmacology (Berl) 2009, 206:731-740.
7. Arad M., Weiner I. Sex-dependent antipsychotic capacity of 17beta-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males. Neuropsychopharmacology 2010, 35:2179-2192.
8. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012, 64:238-258.
9. Balaratnasingam S., Janca A. Brain derived neurotrophic factor: a novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol Ther 2012, 134:116-124.
10. Ban T.A. The role of serendipity in drug discovery. Dialogues Clin Neurosci 2006, 8:335-344.
11. Begliuomini S., Casarosa E., Pluchino N., Lenzi E., Centofanti M., Freschi L., Pieri M., Genazzani A.D., Luisi S., Genazzani A.R. Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. Hum Reprod 2007, 22:995-1002.
12. Bergemann N., Parzer P., Runnebaum B., Resch F., Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med 2007, 37:1427-1436.
13. Bertrand P.P., Paranavitane U.T., Chavez C., Gogos A., Jones M., van den Buuse M. The effect of low estrogen state on serotonin transporter function in mouse hippocampus: a behavioral and electrochemical study. Brain Res 2005, 1064:10-20.
14. Bethea C.L., Lu N.Z., Gundlah C., Streicher J.M. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002, 23:41-100.
15. Blurton-Jones M., Kuan P.N., Tuszynski M.H. Anatomical evidence for transsynaptic influences of estrogen on brain-derived neurotrophic factor expression. J Comp Neurol 2004, 468:347-360.
16. Blurton-Jones M., Tuszynski M.H. Estradiol-induced modulation of estrogen receptor-beta and GABA within the adult neocortex: a potential transsynaptic mechanism for estrogen modulation of BDNF. J Comp Neurol 2006, 499:603-612.
17. Bubar M.J., Cunningham K.A. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 2006, 6:1971-1985.
18. Buckley P.F., Pillai A., Howell K.R. Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry 2011, 24:122-127.
19. Buka S.L., Tsuang M.T., Torrey E.F., Klebanoff M.A., Bernstein D., Yolken R.H. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 2001, 58:1032-1037.
20. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001, 41:237-260.
21. Castle D., Sham P., Murray R. Differences in distribution of ages of onset in males and females with schizophrenia. Schizophr Res 1998, 33:179-183.
22. Castren E., Berninger B., Leingartner A., Lindholm D. Regulation of brain-derived neurotrophic factor mRNA levels in hippocampus by neuronal activity. Prog Brain Res 1998, 117:57-64.
23. Cavus I., Duman R.S. Influence of estradiol, stress, and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats. Biol Psychiatry 2003, 54:59-69.
24. Chang S.S., Renshaw D.C. Psychosis and pregnancy. Compr Ther 1986, 12:36-41.
25. Chapleau C.A., Carlo M.E., Larimore J.L., Pozzo-Miller L. The actions of BDNF on dendritic spine density and morphology in organotypic slice cultures depend on the presence of serum in culture media. J Neurosci Methods 2008, 169:182-190.
26. Chavez C., Gogos A., Jones M.E., van den Buuse M. Psychotropic drug-induced locomotor hyperactivity and prepulse inhibition regulation in male and female aromatase knockout (ArKO) mice: role of dopamine D1 and D2 receptors and dopamine transporters. Psychopharmacology (Berl) 2009, 206:267-279.
27. Chavez C., Hollaus M., Scarr E., Pavey G., Gogos A., van den Buuse M. The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res 2010, 1321:51-59.
28. Cheeran B., Talelli P., Mori F., Koch G., Suppa A., Edwards M., Houlden H., Bhatia K., Greenwood R., Rothwell J.C. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol 2008, 586:5717-5725.
29. Chen da C., Wang J., Wang B., Yang S.C., Zhang C.X., Zheng Y.L., Li Y.L., Wang N., Yang K.B., Xiu M.H., Kosten T.R., Zhang X.Y. Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 2009, 207:375-380.
30. Chen Z.Y., Patel P.D., Sant G., Meng C.X., Teng K.K., Hempstead B.L., Lee F.S. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004, 24:4401-4411.
31. Chlan-Fourney J., Ashe P., Nylen K., Juorio A.V., Li X.M. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res 2002, 954:11-20.
32. Chourbaji S., Hellweg R., Brandis D., Zorner B., Zacher C., Lang U.E., Henn F.A., Hortnagl H., Gass P. Mice with reduced brain-derived neurotrophic factor expression show decreased choline acetyltransferase activity, but regular brain monoamine levels and unaltered emotional behavior. Brain Res Mol Brain Res 2004, 121:28-36.
33. Cohen R.Z., Seeman M.V., Gotowiec A., Kopala L. Earlier puberty as a predictor of later onset of schizophrenia in women. Am J Psychiatry 1999, 156:1059-1064.
34. Crawford D.K., Mangiardi M., Song B., Patel R., Du S., Sofroniew M.V., Voskuhl R.R., Tiwari-Woodruff S.K. Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination. Brain 2010, 133:2999-3016.
35. Cyr M., Calon F., Morissette M., Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci 2002, 27:12-27.
36. Cyr M., Ghribi O., Di Paolo T. Regional and selective effects of oestradiol and progesterone on NMDA and AMPA receptors in the rat brain. J Neuroendocrinol 2000, 12:445-452.
37. D'Souza D.N., Harlan R.E., Garcia M.M. Modulation of glutamate receptor expression by gonadal steroid hormones in the rat striatum. Brain Res Bull 2003, 59:289-292.
38. De Carolis L., Stasi M.A., Serlupi-Crescenzi O., Borsini F., Nencini P. The effects of clozapine on quinpirole-induced non-regulatory drinking and prepulse inhibition disruption in rats. Psychopharmacology (Berl) 2010, 212:105-115.
39. de Olmos S., Bueno A., Bender C., Lorenzo A., de Olmos J. Sex differences and influence of gonadal hormones on MK801-induced neuronal degeneration in the granular retrosplenial cortex of the rat. Brain Struct Funct 2008, 213:229-238.
40. DeCarolis N.A., Eisch A.J. Hippocampal neurogenesis as a target for the treatment of mental illness: a critical evaluation. Neuropharmacology 2010, 58:884-893.
41. Deltheil T., Guiard B.P., Cerdan J., David D.J., Tanaka K.F., Reperant C., Guilloux J.P., Coudore F., Hen R., Gardier A.M. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology 2008, 55:1006-1014.
42. Dluzen D.E., McDermott J.L. Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity. Ann N Y Acad Sci 2004, 1025:205-220.
43. Donahue J.E., Stopa E.G., Chorsky R.L., King J.C., Schipper H.M., Tobet S.A., Blaustein J.D., Reichlin S. Cells containing immunoreactive estrogen receptor-alpha in the human basal forebrain. Brain Res 2000, 856:142-151.
44. Dufy B., Vincent J.D., Fleury H., Du Pasquier P., Gourdji D., Tixier-Vidal A. Dopamine inhibition of action potentials in a prolactin secreting cell line is modulated by oestrogen. Nature 1979, 282:855-857.
45. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001, 52:79-86.
46. Egan M.F., Weinberger D.R., Lu B. Schizophrenia, III: brain-derived neurotropic factor and genetic risk. Am J Psychiatry 2003, 160:1242.
47. Eide F.F., Vining E.R., Eide B.L., Zang K., Wang X.Y., Reichardt L.F. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci 1996, 16:3123-3129.
48. Ernfors P., Lee K.F., Jaenisch R. Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature 1994, 368:147-150.
49. Ernfors P., Wetmore C., Olson L., Persson H. Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family. Neuron 1990, 5:511-526.
50. Faludi G., Dome P., Lazary J. Origins and perspectives of schizophrenia research. Neuropsychopharmacol Hung 2011, 13:185-192.
51. Fester L., Prange-Kiel J., Jarry H., Rune G.M. Estrogen synthesis in the hippocampus. Cell Tissue Res 2011, 345:285-294.
52. Friedman W.J., Olson L., Persson H. Cells that express brain-derived neurotrophic factor mRNA in the developing postnatal rat brain. Eur J Neurosci 1991, 3:688-697.
53. Fung S.J., Webster M.J., Sivagnanasundaram S., Duncan C., Elashoff M., Weickert C.S. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry 2010, 167:1479-1488.
54. Garcia-Segura L.M., Cardona-Gomez P., Naftolin F., Chowen J.A. Estradiol upregulates Bcl-2 expression in adult brain neurons. Neuroreport 1998, 9:593-597.
55. Gavalda N., Perez-Navarro E., Gratacos E., Comella J.X., Alberch J. Differential involvement of phosphatidylinositol 3-kinase and p42/p44 mitogen activated protein kinase pathways in brain-derived neurotrophic factor-induced trophic effects on cultured striatal neurons. Mol Cell Neurosci 2004, 25:460-468.
56. Glausier J.R., Lewis D.A. Dendritic spine pathology in schizophrenia. Neuroscience 2012, in press.
57. Gogos A., Kwek P., Chavez C., van den Buuse M. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors. J Pharmacol Exp Ther 2010, 333:218-227.
58. Gogos A., Kwek P., van den Buuse M. The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia. Psychopharmacology (Berl) 2012, 219:213-224.
59. Gogos A., Martin S., Jones M.E., van den Buuse M. Oestrogen modulation of the effect of 8-OH-DPAT on prepulse inhibition: effects of aromatase deficiency and castration in mice. Psychopharmacology (Berl) 2006, 188:100-110.
60. Gogos A., Nathan P.J., Guille V., Croft R.J., van den Buuse M. Estrogen prevents 5-HT1A receptor-induced disruptions of prepulse inhibition in healthy women. Neuropsychopharmacology 2006, 31:885-889.
61. Gogos A., Van den Buuse M. Estrogen and progesterone prevent disruption of prepulse inhibition by the serotonin-1A receptor agonist 8-hydroxy-2-dipropylaminotetralin. J Pharmacol Exp Ther 2004, 309:267-274.
62. Goldstein J.M., Link B.G. Gender and the expression of schizophrenia. J Psychiatr Res 1988, 22:141-155.
63. Gonzalez-Burgos I., Alejandre-Gomez M., Cervantes M. Spine-type densities of hippocampal CA1 neurons vary in proestrus and estrus rats. Neurosci Lett 2005, 379:52-54.
64. Gonzalez-Pinto A., Mosquera F., Palomino A., Alberich S., Gutierrez A., Haidar K., Vega P., Barbeito S., Ortiz A., Matute C. Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. Int Clin Psychopharmacol 2010, 25:241-245.
65. Goodman Y., Bruce A.J., Cheng B., Mattson M.P. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem 1996, 66:1836-1844.
66. Gorski J.A., Balogh S.A., Wehner J.M., Jones K.R. Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. Neuroscience 2003, 121:341-354.
67. Goulart B.K., de Lima M.N., de Farias C.B., Reolon G.K., Almeida V.R., Quevedo J., Kapczinski F., Schroder N., Roesler R. Ketamine impairs recognition memory consolidation and prevents learning-induced increase in hippocampal brain-derived neurotrophic factor levels. Neuroscience 2010, 167:969-973.
68. Gould E., Woolley C.S., Frankfurt M., McEwen B.S. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci 1990, 10:1286-1291.
69. Gratacos M., Gonzalez J.R., Mercader J.M., de Cid R., Urretavizcaya M., Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 2007, 61:911-922.
70. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011, 16:960-972.
71. Greene R.A. Estrogen and cerebral blood flow: a mechanism to explain the impact of estrogen on the incidence and treatment of Alzheimer's disease. Int J Fertil Womens Med 2000, 45:253-257.
72. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 2007, 41:31-35.
73. Grottick A.J., Bagnol D., Phillips S., McDonald J., Behan D.P., Chalmers D.T., Hakak Y. Neurotransmission- and cellular stress-related gene expression associated with prepulse inhibition in mice. Brain Res Mol Brain Res 2005, 139:153-162.
74. Gruber C.J., Tschugguel W., Schneeberger C., Huber J.C. Production and actions of estrogens. N Engl J Med 2002, 346:340-352.
75. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001, 411:86-89.
76. Guilloux J.P., Douillard-Guilloux G., Kota R., Wang X., Gardier A.M., Martinowich K., Tseng G.C., Lewis D.A., Sibille E. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry 2012, 17:1130-1142.
77. Gundlah C., Kohama S.G., Mirkes S.J., Garyfallou V.T., Urbanski H.F., Bethea C.L. Distribution of estrogen receptor beta (ERbeta) mRNA in hypothalamus, midbrain and temporal lobe of spayed macaque: continued expression with hormone replacement. Brain Res Mol Brain Res 2000, 76:191-204.
78. Haapasalo A., Koponen E., Hoppe E., Wong G., Castren E. Truncated trkB.T1 is dominant negative inhibitor of trkB.TK+-mediated cell survival. Biochem Biophys Res Commun 2001, 280:1352-1358.
79. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003, 28(Suppl 2):17-54.
80. Häfner H., Behrens S., De Vry J., Gattaz W.F. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur Arch Psychiatry Clin Neurosci 1991, 241:65-68.
81. Häfner H., Riecher-Rossler A., An Der Heiden W., Maurer K., Fatkenheuer B., Loffler W. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychol Med 1993, 23:925-940.
82. Hall F.S., Drgonova J., Goeb M., Uhl G.R. Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout mice. Neuropsychopharmacology 2003, 28:1485-1490.
83. Hallonquist J.D., Seeman M.V., Lang M., Rector N.A. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry 1993, 33:207-209.
84. Hambrecht M., Maurer K., Häfner H. Gender differences in schizophrenia in three cultures. Results of the WHO collaborative study on psychiatric disability. Soc Psychiatry Psychiatr Epidemiol 1992, 27:117-121.
85. Hasbi A., Fan T., Alijaniaram M., Nguyen T., Perreault M.L., O'Dowd B.F., George S.R. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci U S A 2009, 106:21377-21382.
86. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., Monteggia L.M., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 2005, 25:372-383.
87. Heese K., Otten U., Mathivet P., Raiteri M., Marescaux C., Bernasconi R. GABA(B) receptor antagonists elevate both mRNA and protein levels of the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) but not neurotrophin-3 (NT-3) in brain and spinal cord of rats. Neuropharmacology 2000, 39:449-462.
88. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Strom A., Treuter E., Warner M., Gustafsson J.A. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007, 87:905-931.
89. Heldt S.A., Stanek L., Chhatwal J.P., Ressler K.J. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry 2007, 12:656-670.
90. Hendrick V., Altshuler L.L., Burt V.K. Course of psychiatric disorders across the menstrual cycle. Harv Rev Psychiatry 1996, 4:200-207.
91. Hill R.A., Murray S.S., Halley P.G., Binder M.D., Martin S.J., van den Buuse M. Brain-derived neurotrophic factor expression is increased in the hippocampus of 5-HT(2C) receptor knockout mice. Hippocampus 2011, 21:434-445.
92. Hill R.A., van den Buuse M. Sex-dependent and region-specific changes in TrkB signaling in BDNF heterozygous mice. Brain Res 2011, 1384:51-60.
93. Hill R.A., Wu Y.W., Kwek P., van den Buuse M. Modulatory effects of sex steroid hormones on brain-derived neurotrophic factor-tyrosine kinase B expression during adolescent development in C57Bl/6 mice. J Neuroendocrinol 2012, 24:774-788.
94. Ho B.C., Milev P., O'Leary D.S., Librant A., Andreasen N.C., Wassink T.H. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 2006, 63:731-740.
95. Hodes G.E., Hill-Smith T.E., Suckow R.F., Cooper T.B., Lucki I. Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in mice. J Pharmacol Exp Ther 2010, 332:266-273.
96. Hofer M., Pagliusi S.R., Hohn A., Leibrock J., Barde Y.A. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 1990, 9:2459-2464.
97. Hoover B.R., Everett C.V., Sorkin A., Zahniser N.R. Rapid regulation of dopamine transporters by tyrosine kinases in rat neuronal preparations. J Neurochem 2007, 101:1258-1271.
98. Hori H., Yoshimura R., Yamada Y., Ikenouchi A., Mitoma M., Ida Y., Nakamura J. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 2007, 22:21-27.
99. Huang E.J., Reichardt L.F. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003, 72:609-642.
100. Huang T.L., Lee C.T. Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatr Res 2006, 40:664-668.
101. Ikeda Y., Yahata N., Ito I., Nagano M., Toyota T., Yoshikawa T., Okubo Y., Suzuki H. Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr Res 2008, 101:58-66.
102. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
103. Iritani S., Niizato K., Nawa H., Ikeda K., Emson P.C. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:801-807.
104. Ivanova T., Kuppers E., Engele J., Beyer C. Estrogen stimulates brain-derived neurotrophic factor expression in embryonic mouse midbrain neurons through a membrane-mediated and calcium-dependent mechanism. J Neurosci Res 2001, 66:221-230.
105. Ji Y., Pang P.T., Feng L., Lu B. Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. Nat Neurosci 2005, 8:164-172.
106. Joffe H., Cohen L.S. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge?. Biol Psychiatry 1998, 44:798-811.
107. Kadish I., Van Groen T. Low levels of estrogen significantly diminish axonal sprouting after entorhinal cortex lesions in the mouse. J Neurosci 2002, 22:4095-4102.
108. Kaplan D.R., Miller F.D. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000, 10:381-391.
109. Karege F., Schwald M., Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002, 328:261-264.
110. Katoh-Semba R., Takeuchi I.K., Semba R., Kato K. Distribution of brain-derived neurotrophic factor in rats and its changes with development in the brain. J Neurochem 1997, 69:34-42.
111. Kendell R.E., Chalmers J.C., Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 1987, 150:662-673.
112. Kendler K.S., Diehl S.R. The genetics of schizophrenia: a current, genetic-epidemiologic perspective. Schizophr Bull 1993, 19:261-285.
113. Kiss A., Delattre A.M., Pereira S.I., Carolino R.G., Szawka R.E., Anselmo-Franci J.A., Zanata S.M., Ferraz A.C. 17beta-estradiol replacement in young, adult and middle-aged female ovariectomized rats promotes improvement of spatial reference memory and an antidepressant effect and alters monoamines and BDNF levels in memory- and depression-related brain areas. Behav Brain Res 2012, 227:100-108.
114. Klein A.B., Santini M.A., Aznar S., Knudsen G.M., Rios M. Changes in 5-HT2A-mediated behavior and 5-HT2A- and 5-HT1A receptor binding and expression in conditional brain-derived neurotrophic factor knock-out mice. Neuroscience 2010, 169:1007-1016.
115. Klein R., Conway D., Parada L.F., Barbacid M. The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell 1990, 61:647-656.
116. Klug M., Hill R.A., Choy K.H., Kyrios M., Hannan A.J., van den Buuse M. Long-term behavioral and NMDA receptor effects of young-adult corticosterone treatment in BDNF heterozygous mice. Neurobiol Dis 2012, 46:722-731.
117. Klug M., van den Buuse M. Chronic cannabinoid treatment during young adulthood induces sex-specific behavioural deficits in maternally separated rats. Behav Brain Res 2012, 233:305-313.
118. Knoblauch R., Garabedian M.J. Role for Hsp90-associated cochaperone p23 in estrogen receptor signal transduction. Mol Cell Biol 1999, 19:3748-3759.
119. Komulainen P., Pedersen M., Hanninen T., Bruunsgaard H., Lakka T.A., Kivipelto M., Hassinen M., Rauramaa T.H., Pedersen B.K., Rauramaa R. BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study. Neurobiol Learn Mem 2008, 90:596-603.
120. Koster A., Lajer M., Lindhardt A., Rosenbaum B. Gender differences in first episode psychosis. Soc Psychiatry Psychiatr Epidemiol 2008, 43:940-946.
121. Kozisek M.E., Middlemas D., Bylund D.B. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther 2008, 117:30-51.
122. Kramar E.A., Chen L.Y., Brandon N.J., Rex C.S., Liu F., Gall C.M., Lynch G. Cytoskeletal changes underlie estrogen's acute effects on synaptic transmission and plasticity. J Neurosci 2009, 29:12982-12993.
123. Kritzer M.F., Creutz L.M. Region and sex differences in constituent dopamine neurons and immunoreactivity for intracellular estrogen and androgen receptors in mesocortical projections in rats. J Neurosci 2008, 28:9525-9535.
124. Kritzer M.F., Kohama S.G. Ovarian hormones differentially influence immunoreactivity for dopamine beta- hydroxylase, choline acetyltransferase, and serotonin in the dorsolateral prefrontal cortex of adult rhesus monkeys. J Comp Neurol 1999, 409:438-451.
125. Kulkarni J., de Castella A., Fitzgerald P.B., Gurvich C.T., Bailey M., Bartholomeusz C., Burger H. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008, 65:955-960.
126. Kuppers E., Krust A., Chambon P., Beyer C. Functional alterations of the nigrostriatal dopamine system in estrogen receptor-alpha knockout (ERKO) mice. Psychoneuroendocrinology 2008, 33:832-838.
127. Lambert T.J., Castle D.J. Pharmacological approaches to the management of schizophrenia. Med J Aust 2003, 178(Suppl):S57-61.
128. Lasiuk G.C., Hegadoren K.M. The effects of estradiol on central serotonergic systems and its relationship to mood in women. Biol Res Nurs 2007, 9:147-160.
129. Lee A.H., Lange C., Ricken R., Hellweg R., Lang U.E. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol 2011, 31:334-336.
130. Levin E.R. Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol 2001, 91:1860-1867.
131. Lewine R. Schizophrenia: an amotivational syndrome in men. Can J Psychiatry 1985, 30:316-318.
132. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 2012, 35:57-67.
133. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005, 6:312-324.
134. Liu F., Day M., Muniz L.C., Bitran D., Arias R., Revilla-Sanchez R., Grauer S., Zhang G., Kelley C., Pulito V., Sung A., Mervis R.F., Navarra R., Hirst W.D., Reinhart P.H., Marquis K.L., Moss S.J., Pangalos M.N., Brandon N.J. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci 2008, 11:334-343.
135. Llorente R., Miguel-Blanco C., Aisa B., Lachize S., Borcel E., Meijer O.C., Ramirez M.J., De Kloet E.R., Viveros M.P. Long term sex-dependent psychoneuroendocrine effects of maternal deprivation and juvenile unpredictable stress in rats. J Neuroendocrinol 2011, 23:329-344.
136. Lu B. Pro-region of neurotrophins: role in synaptic modulation. Neuron 2003, 39:735-738.
137. Luberg K., Wong J., Weickert C.S., Timmusk T. Human TrkB gene: novel alternative transcripts, protein isoforms and expression pattern in the prefrontal cerebral cortex during postnatal development. J Neurochem 2010, 113:952-964.
138. Lyons W.E., Mamounas L.A., Ricaurte G.A., Coppola V., Reid S.W., Bora S.H., Wihler C., Koliatsos V.E., Tessarollo L. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A 1999, 96:15239-15244.
139. MacLusky N.J., Clark A.S., Naftolin F., Goldman-Rakic P.S. Estrogen formation in the mammalian brain: possible role of aromatase in sexual differentiation of the hippocampus and neocortex. Steroids 1987, 50:459-474.
140. MacQueen G.M., Ramakrishnan K., Croll S.D., Siuciak J.A., Yu G., Young L.T., Fahnestock M. Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression. Behav Neurosci 2001, 115:1145-1153.
141. Mahe V., Dumaine A. Oestrogen withdrawal associated psychoses. Acta Psychiatr Scand 2001, 104:323-331.
142. Mahe V., Montagnon F., Nartowski J., Dumane A. Post-abortion mania. Br J Psychiatry 1999, 175:389-390.
143. Markham J.A. Sex steroids and schizophrenia. Rev Endocr Metab Disord 2012, 13:187-207.
144. Matsuki H., Shirayama Y., Hashimoto K., Tanaka A., Minabe Y. Effects of age and gender on the expression of brain-derived neurotrophic factor mRNA in rat retrosplenial cortex following administration of dizocilpine. Neuropsychopharmacology 2001, 25:258-266.
145. McNeil T.F., Cantor-Graae E., Ismail B. Obstetric complications and congenital malformation in schizophrenia. Brain Res Brain Res Rev 2000, 31:166-178.
146. McQueen J.K., Wilson H., Fink G. Estradiol-17 beta increases serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain. Brain Res Mol Brain Res 1997, 45:13-23.
147. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999, 21:106S-115S.
148. Meltzer H.Y., Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991, 43:587-604.
149. Middlemas D.S., Lindberg R.A., Hunter T. TrkB, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors. Mol Cell Biol 1991, 11:143-153.
150. Miranda R.C., Sohrabji F., Toran-Allerand C.D. Presumptive estrogen target neurons express mRNAs for both the neurotrophins and neurotrophin receptors: a basis for potential developmental interactions of estrogen with the neurotrophins. Mol Cell Neurosci 1993, 4:510-525.
151. Molendijk M.L., Bus B.A., Spinhoven P., Penninx B.W., Kenis G., Prickaerts J., Voshaar R.C., Elzinga B.M. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011, 16:1088-1095.
152. Monteggia L.M., Luikart B., Barrot M., Theobold D., Malkovska I., Nef S., Parada L.F., Nestler E.J. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry 2007, 61:187-197.
153. Morris H.M., Hashimoto T., Lewis D.A. Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb Cortex 2008, 18:1575-1587.
154. Morse J.K., Scheff S.W., DeKosky S.T. Gonadal steroids influence axon sprouting in the hippocampal dentate gyrus: a sexually dimorphic response. Exp Neurol 1986, 94:649-658.
155. Mowla S.J., Farhadi H.F., Pareek S., Atwal J.K., Morris S.J., Seidah N.G., Murphy R.A. Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J Biol Chem 2001, 276:12660-12666.
156. Murer M.G., Yan Q., Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2001, 63:71-124.
157. Murphy D.D., Cole N.B., Greenberger V., Segal M. Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci 1998, 18:2550-2559.
158. Narisawa-Saito M., Nawa H. Differential regulation of hippocampal neurotrophins during aging in rats. J Neurochem 1996, 67:1124-1131.
159. Nawa H., Bessho Y., Carnahan J., Nakanishi S., Mizuno K. Regulation of neuropeptide expression in cultured cerebral cortical neurons by brain-derived neurotrophic factor. J Neurochem 1993, 60:772-775.
160. Nawa H., Pelleymounter M.A., Carnahan J. Intraventricular administration of BDNF increases neuropeptide expression in newborn rat brain. J Neurosci 1994, 14:3751-3765.
161. Osterlund M., Kuiper G.G., Gustafsson J.A., Hurd Y.L. Differential distribution and regulation of estrogen receptor-alpha and -beta mRNA within the female rat brain. Brain Res Mol Brain Res 1998, 54:175-180.
162. Osterlund M.K., Keller E., Hurd Y.L. The human forebrain has discrete estrogen receptor alpha messenger RNA expression: high levels in the amygdaloid complex. Neuroscience 2000, 95:333-342.
163. Palomino A., Vallejo-Illarramendi A., Gonzalez-Pinto A., Aldama A., Gonzalez-Gomez C., Mosquera F., Gonzalez-Garcia G., Matute C. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 2006, 86:321-322.
164. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37:1553-1561.
165. Pantelis C., Lambert T.J. Managing patients with " treatment-resistant" schizophrenia. Med J Aust 2003, 178(Suppl.):S62-66.
166. Payne J.L. The role of estrogen in mood disorders in women. Int Rev Psychiatry 2003, 15:280-290.
167. Pezawas L., Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., Egan M.F., Meyer-Lindenberg A., Weinberger D.R. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004, 24:10099-10102.
168. Pillai A. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals 2008, 16:183-193.
169. Pillai A., Kale A., Joshi S., Naphade N., Raju M.S., Nasrallah H., Mahadik S.P. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 2010, 13:535-539.
170. Rapoport JL, Giedd JN, Gogtay N (in press) Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry.
171. Register T.C., Shively C.A., Lewis C.E. Expression of estrogen receptor alpha and beta transcripts in female monkey hippocampus and hypothalamus. Brain Res 1998, 788:320-322.
172. Reis H.J., Nicolato R., Barbosa I.G., Teixeira do Prado P.H., Romano-Silva M.A., Teixeira A.L. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neurosci Lett 2008, 439:157-159.
173. Ren-Patterson R.F., Cochran L.W., Holmes A., Lesch K.P., Lu B., Murphy D.L. Gender-dependent modulation of brain monoamines and anxiety-like behaviors in mice with genetic serotonin transporter and BDNF deficiencies. Cell Mol Neurobiol 2006, 26:755-780.
174. Riecher-Rossler A., Kulkarni J. Estrogens and gonadal function in schizophrenia and related psychoses. Curr Top Behav Neurosci 2011, 8:155-171.
175. Riecher-Rossler A., Loffler W., Munk-Jorgensen P. What do we really know about late-onset schizophrenia?. Eur Arch Psychiatry Clin Neurosci 1997, 247:195-208.
176. Rizos E.N., Rontos I., Laskos E., Arsenis G., Michalopoulou P.G., Vasilopoulos D., Gournellis R., Lykouras L. Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1308-1311.
177. Roseman A.S., McGregor C., Thornton J.E. Estradiol attenuates the cognitive deficits in the novel object recognition task induced by sub-chronic phencyclidine in ovariectomized rats. Behav Brain Res 2012, 233:105-112.
178. Rumajogee P., Madeira A., Verge D., Hamon M., Miquel M.C. Up-regulation of the neuronal serotoninergic phenotype in vitro: BDNF and cAMP share Trk B-dependent mechanisms. J Neurochem 2002, 83:1525-1528.
179. Rune G.M., Lohse C., Prange-Kiel J., Fester L., Frotscher M. Synaptic plasticity in the hippocampus: effects of estrogen from the gonads or hippocampus?. Neurochem Res 2006, 31:145-155.
180. Rybakowski J.K. BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 2008, 9:1589-1593.
181. Sanchez M.G., Bourque M., Morissette M., Di Paolo T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010, 16:e43-e71.
182. Saylor A.J., McGinty J.F. Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice. Genes Brain Behav 2008, 7:906-914.
183. Scarr E., Pavey G., Copolov D., Dean B. Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects. Schizophr Res 2004, 71:383-392.
184. Scharfman H.E., Maclusky N.J. Similarities between actions of estrogen and BDNF in the hippocampus: coincidence or clue?. Trends Neurosci 2005, 28:79-85.
185. Scharfman H.E., MacLusky N.J. Estrogen and brain-derived neurotrophic factor (BDNF) in hippocampus: complexity of steroid hormone-growth factor interactions in the adult CNS. Front Neuroendocrinol 2006, 27:415-435.
186. Scharfman H.E., MacLusky N.J. Estrogen-growth factor interactions and their contributions to neurological disorders. Headache 2008, 48(Suppl. 2):S77-89.
187. Scharfman H.E., Mercurio T.C., Goodman J.H., Wilson M.A., MacLusky N.J. Hippocampal excitability increases during the estrous cycle in the rat: a potential role for brain-derived neurotrophic factor. J Neurosci 2003, 23:11641-11652.
188. Seeman M.V. Interaction of sex, age, and neuroleptic dose. Compr Psychiatry 1983, 24:125-128.
189. Seeman M.V. Menstrual exacerbation of schizophrenia symptoms. Acta Psychiatr Scand 2012, 125:363-371.
190. Seeman M.V., Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990, 16:185-194.
191. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987, 1:133-152.
192. Shaikh M., Hall M.H., Schulze K., Dutt A., Walshe M., Williams I., Constante M., Picchioni M., Toulopoulou T., Collier D., Rijsdijk F., Powell J., Arranz M., Murray R.M., Bramon E. Do COMT, BDNF and NRG1 polymorphisms influence P50 sensory gating in psychosis?. Psychol Med 2011, 41:263-276.
193. Shalev I., Lerer E., Israel S., Uzefovsky F., Gritsenko I., Mankuta D., Ebstein R.P., Kaitz M. BDNF Val66Met polymorphism is associated with HPA axis reactivity to psychological stress characterized by genotype and gender interactions. Psychoneuroendocrinology 2009, 34:382-388.
194. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 2003, 351:111-114.
195. Snigdha S., Neill J.C., McLean S.L., Shemar G.K., Cruise L., Shahid M., Henry B. Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain. J Mol Neurosci 2011, 43:337-345.
196. Sohrabji F., Miranda R.C., Toran-Allerand C.D. Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proc Natl Acad Sci U S A 1995, 92:11110-11114.
197. Spencer-Segal J.L., Tsuda M.C., Mattei L., Waters E.M., Romeo R.D., Milner T.A., McEwen B.S., Ogawa S. Estradiol acts via estrogen receptors alpha and beta on pathways important for synaptic plasticity in the mouse hippocampal formation. Neuroscience 2012, 202:131-146.
198. Srivastava D.P. Two-step wiring plasticity - a mechanism for estrogen-induced rewiring of cortical circuits. J Steroid Biochem Mol Biol 2012, 131:17-23.
199. Srivastava D.P., Woolfrey K.M., Jones K.A., Shum C.Y., Lash L.L., Swanson G.T., Penzes P. Rapid enhancement of two-step wiring plasticity by estrogen and NMDA receptor activity. Proc Natl Acad Sci U S A 2008, 105:14650-14655.
200. Srivastava D.P., Woolfrey K.M., Liu F., Brandon N.J., Penzes P. Estrogen receptor ss activity modulates synaptic signaling and structure. J Neurosci 2010, 30:13454-13460.
201. Sumner B.E., Grant K.E., Rosie R., Hegele-Hartung C., Fritzemeier K.H., Fink G. Effects of tamoxifen on serotonin transporter and 5-hydroxytryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Brain Res Mol Brain Res 1999, 73:119-128.
202. Sutcliffe J.S., Rhaman F., Marshall K.M., Neill J.C. Oestradiol attenuates the cognitive deficit induced by acute phencyclidine treatment in mature female hooded-Lister rats. J Psychopharmacol 2008, 22:918-922.
203. Szapacs M.E., Mathews T.A., Tessarollo L., Ernest Lyons W., Mamounas L.A., Andrews A.M. Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. J Neurosci Methods 2004, 140:81-92.
204. Szeszko P.R., Lipsky R., Mentschel C., Robinson D., Gunduz-Bruce H., Sevy S., Ashtari M., Napolitano B., Bilder R.M., Kane J.M., Goldman D., Malhotra A.K. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 2005, 10:631-636.
205. Taber K.H., Murphy D.D., Blurton-Jones M.M., Hurley R.A. An update on estrogen: higher cognitive function, receptor mapping, neurotrophic effects. J Neuropsychiatry Clin Neurosci 2001, 13:313-317.
206. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., Koizumi S., Wakabayashi K., Takahashi H., Someya T., Nawa H. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000, 5:293-300.
207. Tamminga C. Glutamatergic aspects of schizophrenia. Br J Psychiatry Suppl 1999, 37:12-15.
208. Tan Y.L., Zhou D.F., Cao L.Y., Zou Y.Z., Zhang X.Y. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 2005, 382:27-32.
209. Teixeira C., Reed J.C., Pratt M.A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995, 55:3902-3907.
210. Teng H.K., Teng K.K., Lee R., Wright S., Tevar S., Almeida R.D., Kermani P., Torkin R., Chen Z.Y., Lee F.S., Kraemer R.T., Nykjaer A., Hempstead B.L. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 2005, 25:5455-5463.
211. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995, 270:593-598.
212. Thompson Ray M., Weickert C.S., Wyatt E., Webster M.J. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011, 36:195-203.
213. Thorup A., Petersen L., Jeppesen P., Ohlenschlaeger J., Christensen T., Krarup G., Jorgensen P., Nordentoft M. Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study. J Nerv Ment Dis 2007, 195:396-405.
214. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002, 110:249-257.
215. Tyler W.J., Pozzo-Miller L. Miniature synaptic transmission and BDNF modulate dendritic spine growth and form in rat CA1 neurones. J Physiol 2003, 553:497-509.
216. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010, 36:246-270.
217. Vigers A.J., Amin D.S., Talley-Farnham T., Gorski J.A., Xu B., Jones K.R. Sustained expression of brain-derived neurotrophic factor is required for maintenance of dendritic spines and normal behavior. Neuroscience 2012, 212:1-18.
218. Walf A.A., Frye C.A. Rapid and estrogen receptor beta mediated actions in the hippocampus mediate some functional effects of estrogen. Steroids 2008, 73:997-1007.
219. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003, 8:592-610.
220. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., Hyde T.M., Herman M.M., Weinberger D.R., Kleinman J.E. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2005, 10:637-650.
221. Wong J., Woon H.G., Weickert C.S. Full length TrkB potentiates estrogen receptor alpha mediated transcription suggesting convergence of susceptibility pathways in schizophrenia. Mol Cell Neurosci 2011, 46:67-78.
222. Woo N.H., Lu B. Regulation of cortical interneurons by neurotrophins: from development to cognitive disorders. Neuroscientist 2006, 12:43-56.
223. Woolley C.S. Estrogen-mediated structural and functional synaptic plasticity in the female rat hippocampus. Horm Behav 1998, 34:140-148.
224. Woolley C.S., McEwen B.S. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci 1992, 12:2549-2554.
225. Woolley C.S., Weiland N.G., McEwen B.S., Schwartzkroin P.A. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J Neurosci 1997, 17:1848-1859.
226. Woolley M.L., Waters K.A., Gartlon J.E., Lacroix L.P., Jennings C., Shaughnessy F., Ong A., Pemberton D.J., Harries M.H., Southam E., Jones D.N., Dawson L.A. Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. Psychopharmacology (Berl) 2009, 202:343-354.
227. Wu Y.C., Hill R.A., Klug M., van den Buuse M. Sex-specific and region-specific changes in BDNF-TrkB signalling in the hippocampus of 5-HT1A receptor and BDNF single and double mutant mice. Brain Res 2012, 1452:10-17.
228. Xiu M.H., Hui L., Dang Y.F., Hou T.D., Zhang C.X., Zheng Y.L., Chen da C., Kosten T.R., Zhang X.Y. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1508-1512.
229. Xu B., Gottschalk W., Chow A., Wilson R.I., Schnell E., Zang K., Wang D., Nicoll R.A., Lu B., Reichardt L.F. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci 2000, 20:6888-6897.
230. Xu H., Chen Z., He J., Haimanot S., Li X., Dyck L., Li X.M. Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus 2006, 16:551-559.
231. Yoshii A., Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 2010, 70:304-322.
232. Yoshimura R., Hori H., Sugita A., Ueda N., Kakihara S., Umene W., Nakano Y., Shinkai K., Mitoma M., Ohta M., Shinkai T., Nakamura J. Treatment with risperidone for 4weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1072-1077.
233. Zetterstrom T.S., Pei Q., Madhav T.R., Coppell A.L., Lewis L., Grahame-Smith D.G. Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain. Neuropharmacology 1999, 38:1063-1073.
234. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009, 5:311-322.